Clinical Trial

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 30, 2025 (before its estimated November 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purposes of the study are to evaluate the Safety, Tolerability, and Immunogenicity of different dose levels of recombinant herpes zoster vaccine with 2 doses 60 days apart in healthy subjects aged 40 years and older.
Trial Details
NCT Number NCT06801509
Lead Sponsor Sinocelltech Ltd.
Conditions Herpes Zoster
Enrollment 540 participants
Start Date 2025-02-15
Primary Completion 2025-11-10 (estimated)
Study Completion 2027-10-10 (estimated)
Updated on ClinicalTrials.gov 2025-01-30